Tag: Big Pharma
Clinical Trials
Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data
Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients...
Business & Industry
J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant
Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move...
Clinical Trials
AstraZeneca Breztri Reports Positive Phase III Trial Results
Results from the Phase III KALOS and LOGOS trials evaluating AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) in patients with uncontrolled asthma have...
Business & Industry
Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies
Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move...
Clinical Trials
Study Finds Fenebrutinib Cuts Disability Progression In PPMS
Roche announced late-breaking Phase III data showing that fenebrutinib reduces disability progression in PPMS, marking the first investigational advance for primary progressive multiple sclerosis...
Drug Research
Drug Delivery Innovations Supporting Personalized Medicine
Investigation into the technological advancements that enable individualized therapeutic regimens, focusing on precision dosing, genetic tailoring, and smart delivery systems.
Business & Industry
Seamless Therapeutics and Eli Lilly Hearing Loss Collaboration
Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read